Systemic treatment for unresectable hepatocellular carcinoma
Issued Date
2023-03-14
Resource Type
ISSN
10079327
eISSN
22192840
Scopus ID
2-s2.0-85151042744
Pubmed ID
36970588
Journal Title
World Journal of Gastroenterology
Volume
29
Issue
10
Start Page
1551
End Page
1568
Rights Holder(s)
SCOPUS
Bibliographic Citation
World Journal of Gastroenterology Vol.29 No.10 (2023) , 1551-1568
Suggested Citation
Leowattana W., Leowattana T., Leowattana P.T. Systemic treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology Vol.29 No.10 (2023) , 1551-1568. 1568. doi:10.3748/wjg.v29.i10.1551 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82360
Title
Systemic treatment for unresectable hepatocellular carcinoma
Author(s)
Other Contributor(s)
Abstract
Hepatocellular carcinoma (HCC) is most commonly found in the context of liver cirrhosis and, in rare cases, in a healthy liver. Its prevalence has risen in recent years, particularly in Western nations, due to the increasing frequency of nonalcoholic fatty liver disease. Advanced HCC has a poor prognosis. For many years, the only proven therapy for unresectable HCC (uHCC) was sorafenib, a tyrosine kinase inhibitor. Recently, the synergistic effect of an immune checkpoint inhibitor, atezolizumab, and bevacizumab outperformed sorafenib alone in terms of survival, making it the recommended first-line therapy. Other multikinase inhibitors, lenvatinib and regorafenib, were also recommended as first and second-line drugs, respectively. Intermediate-stage HCC patients with retained liver function, particularly uHCC without extrahepatic metastasis, may benefit from trans-arterial chemoembolization. The current problem in uHCC is selecting a patient for the best treatment while considering the preexisting liver condition and liver function. Indeed, all study patients had a Child-Pugh class A, and the best therapy for other individuals is unknown. Additionally, in the absence of a medical contraindication, atezolizumab could be combined with bevacizumab for uHCC systemic therapy. Several studies are now underway to evaluate immune checkpoint inhibitors in combination with anti-angiogenic drugs, and the first findings are encouraging. The paradigm of uHCC therapy is changing dramatically, and many obstacles remain for optimum patient management in the near future. The purpose of this commentary review was to give an insight into current systemic treatment options for patients with uHCC who are not candidates for surgery to cure the disease.